Lugano, Switzerland, 5 June 2025 – The ESMO Gynaecological Cancers Congress 2025 is dedicated to advancing the understanding, management, and treatment of gynaecological malignancies. Between 19-21 June, experts from around the world will convene in Vienna, Austria, to present and discuss the latest research in the field. Topics will range from recent advances in combination therapies, targeted agents, antibody-drug conjugates (ADCs) and immunotherapy to emerging treatment strategies for rare gynaecological cancers.
The congress will be accessible both in person and online, with all sessions available via live stream on the Virtual Congress Platform.
Programme picks
-
Novel data on the survival benefits of immunotherapy combinations in cervical cancer, and insights into their role and efficacy in various patient groups with ovarian and endometrial cancers.
-
Results on efficacy and safety of a phase 3 trial investigating a new combination therapy for the treatment of platinum-resistant ovarian cancer.
-
Related content: 70O
-
-
Innovative approaches using antibody-drug conjugates for treating platinum-sensitive ovarian cancer and for exploring targeted treatment strategies in high-grade serous ovarian cancer.
-
Insights into liquid biopsies and biomarkers in hard-to-treat ovarian cancers, along with emerging therapies for endometrial cancers and other rare gynaecological malignancies with limited treatment options.
-
Related content: 68O, 69O, 44P, educational session
-
-
“Ernst Wertheim: Lessons from the past and insights gained through history”, Keynote lecture by Christian Marth, 20 June, 12:10 - 12:40 CEST
The abstracts will be published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ESMO Gynaecological Cancers Congress 2025. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditation will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
ESMO Press Office
press@esmo.org
Notes to editors
Please make sure to use the official name of the meeting in your reports: ESMO Gynaecological Cancers Congress 2025 and the official congress hashtag #ESMOGynae25. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Facebook, Instagram, YouTube, Bluesky.
About the European Society for Medical Oncology (ESMO)
Representing more than 40,000 oncology professionals from 179 countries and territories, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org